Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Deferred Taxes (2022 - 2025)

Historic Deferred Taxes for Harmony Biosciences Holdings (HRMY) over the last 4 years, with Q3 2025 value amounting to -$3.9 million.

  • Harmony Biosciences Holdings' Deferred Taxes rose 1964.8% to -$3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$21.4 million, marking a year-over-year increase of 34.48%. This contributed to the annual value of -$29.3 million for FY2024, which is 11833.22% down from last year.
  • Per Harmony Biosciences Holdings' latest filing, its Deferred Taxes stood at -$3.9 million for Q3 2025, which was up 1964.8% from -$6.5 million recorded in Q2 2025.
  • Harmony Biosciences Holdings' Deferred Taxes' 5-year high stood at $1.1 million during Q4 2023, with a 5-year trough of -$14.3 million in Q2 2024.
  • Over the past 4 years, Harmony Biosciences Holdings' median Deferred Taxes value was -$4.3 million (recorded in 2022), while the average stood at -$5.1 million.
  • Per our database at Business Quant, Harmony Biosciences Holdings' Deferred Taxes soared by 12633.68% in 2023 and then plummeted by 69768.48% in 2024.
  • Quarter analysis of 4 years shows Harmony Biosciences Holdings' Deferred Taxes stood at -$4.3 million in 2022, then surged by 126.34% to $1.1 million in 2023, then tumbled by 697.68% to -$6.7 million in 2024, then soared by 42.18% to -$3.9 million in 2025.
  • Its last three reported values are -$3.9 million in Q3 2025, -$6.5 million for Q2 2025, and -$4.3 million during Q1 2025.